Clinical Trials
The Gammaglobulin Alzheimer’s Partnership Study (GAP)
This is a Phase III study of intravenous immunoglobulin (“IGIV”) in mild to moderate AD. Men and women age 50 to 85 with mild to moderate AD may be eligible to participate. For more information, please contact Ruth Tejeda at 212-305-7661 or rbt41@columbia.edu.
Study of LY2062430 Administered by IV Infusion in Mild to Moderate Alzheimer’s Disease
This is a Phase III study of LY2062430, an anti-amyloid beta monoclonal antibody, administered by IV infusion. Individuals with mild to moderate probable AD who are 55 years of age or older may be eligible to participate. For more information, please contact Lynda Mules at 212-305-2077.
Study of Bapineuzumab (AAB-001, ELN15727) in Mild to Moderate Alzheimer's Disease
This is a Phase III study of bapineuzumab administered by IV infusion which researchers hope will attach to the amyloid protein in the brain and help the body to remove it. Individuals diagnosed with probable AD who are 50 to 88 years old may be eligible to participate. For more information, please contact Evelyn Dominguez at 212-305-2371 or edd5@columbia.edu.
Study of BMS-708163 in Patients with Mild to Moderate Alzheimer's Disease
This is a Phase II study of the safety and tolerability of BMS-708163, an oral compound, in men and women age 50-90 who have been diagnosed with mild to moderate AD. The study includes a 12-week treatment period followed by a 12-week follow-up period. For more information, please contact Evelyn Dominguez at 212-305-2371 or edd5@columbia.edu.
Study of Bapineuzumab (AAB-001) Administered Subcutaneously in Mild to Moderate Alzheimer’s Disease
This is a Phase II study of bapineuzumab administered by injection. Men and women with mild to moderate AD who are 50 to 89 years old may be eligible to participate. For more information, please contact Evelyn Dominguez at 212-305-2371 or edd5@columbia.edu.
Study of ACC-001 Administered Subcutaneously in Alzheimer’s Disease
This is a Phase IIa research study of ACC-001 administered by injection. Men and women with mild to moderate AD who are 50 to 85 years old may be eligible to participate. For more information, please contact Evelyn Dominguez at 212-305-2371.
Antipsychotic Medication Treatment of Psychosis and Behavioral Dyscontrol in Alzheimer's Disease Study
This research study, funded by the National Institute of Aging, uses risperidone (an FDA-approved antipsychotic medication) to treat people with Alzheimer's disease who suffer from hallucinations, delusions, agitation, and/or aggression. Treatment continues over a period of 48 weeks. Each eligible participant must have a family member or caregiver who can assist with adherence to treatment and provide information during the research study. For further information, please contact Karine Cunqueiro at 212-543-6132.
Antidepressant Treatment Studies for Combined Depression and Memory Complaints
We are currently conducting medication treatment studies for individuals (age 50+) experiencing both depression and mild memory and/or concentration difficulties. The studies offer both neuropsychological testing for memory and psychiatric evaluation of mood prior to and during the period of treatment. Treatment in our clinic is provided for eligible individuals at no cost for at least 6 months. For further information, please contact Amma Baker at 212-543-5067.
FRONTOTEMPORAL DEMENTIA
Study of Memantine in Frontotemporal Dementia
This is a Phase IV research study to determine if memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. English-speaking men and women who are 40 to 80 years old and who have been diagnosed with frontotemporal dementia (FTD) or semantic dementia (SD) may be eligible. For further information, please contact Lynda Mules at 212-305-2077.
Neuroimaging Studies
PET Scan Research Study for People with Alzheimer’s Disease and Healthy Volunteers
We are recruiting participants for a PET Scan study to see if an investigational PET imaging compound could help improve detection, diagnosis and treatment of Alzheimer’s disease in the future. People at least 55 years of age (females must no longer be of childbearing potential) and who are in good general health with no memory problems OR have been recently diagnosed with Alzheimer’s disease may be eligible to participate. For further information, please contact Lynda Mules at 212-305-2077 or lm2538@columbia.edu
Brain Imaging Study Measuring Changes in Cerebral Blood Flow and Cognition with Age
We are seeking healthy individuals and people with memory complaints or with Alzheimer’s disease, age 55 to 85, to participate in a research study using Arterial Spin Labeling (ASL), a technique that uses MRI to measure cerebral blood flow in the brain. The study consists of three visits and includes an MRI and memory testing, and participants will be compensated. Please contact Abbey Frawley at 212-305-7846 for more information.
.
Other Studies
Genetic Linkage Study
We are seeking families of all nationalities and backgrounds for a study that seeks to identify genes that may increase the risk for developing Alzheimer's disease (AD). If your family has at least two living siblings diagnosed with AD who are 60 years old or older, please call Vincent Santana at (800) 243-5828 or Jennifer Williamson at (212) 305-4655. .
Predictors Study
This research study is for people who are 55 to 90 years old who have been diagnosed with Alzheimer’s disease and/or Dementia with Lewy Bodies. Participation includes initial medical evaluation and testing to assess memory and cognitive functions. This longitudinal study requires bi-annual visits which include memory testing and answering questions about daily activities. For more information, please call 212-305-1987.
Mild Cognitive Impairment: Course and Predictors of Outcome
This research study for people with and without memory complaints who are 55 to 90 years old includes medical evaluation by physicians who specialize in memory disorders, and testing to assess memory and intellectual functions. Visits and monitoring will take place annually for 7 years. At the initial visit only, an MRI scan, two PET scans and a lumbar puncture will be performed. Participants will receive reimbursement. For more information, please call Katrina Cuasay at 212-543-5025.
African American Genetics Study
The African American Genetics Study looks at genetic risk factors for Alzheimer’s disease among African Americans. This is for African American men and women over the age of 60. The study involves an in-person interview at your home or at Columbia University Medical Center to include memory and thinking tests, questions about your health and experiences, and a blood draw. For more information on this opportunity,, call Raquel Cabo at 212-305-1893.
Additional Information
Brain Donation Program "Give the Gift of Knowledge"
Brain donation allows valuable information to be obtained regarding normal aging and diseases that affect memory. This information may be useful towards the goal of developing more effective treatment strategies. If you or a family member wish to learn more about this program, please call Arlene Lawton, RN at 212-305-9086.
Lucy G. Moses Center for Memory and Behavioral Disorders
Changes in memory and thinking abilities can occur from a variety of conditions, not just Alzheimer's disease. Taub Institute specialists offer a thorough multidisciplinary evaluation of memory and thinking difficulties at two locations: The Neurological Institute, 710 West 168th Street, New York, NY 10032; and Columbia Presbyterian Eastside, 16 East 60th Street, New York, NY 10022. For Appointments call: (212) 305-6939.
